Clinical significance and usefulness of soluble heparin binding-epidermal growth factor in gastric cancer

Hye Won Chung, Hoon Young Kong, Jong-Baeck Lim

Hye Won Chung, Department of Internal Medicine, Division of Gastroenterology, International St. Mary’s Hospital, Incheon Metropolitan City, Seoul 137-701, South Korea
Hoon Young Kong, Jong-Baeck Lim, Department of Laboratory Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul 120-752, South Korea

Author contributions: Chung HW and Lim JB contributed the conception and design of the study; Chung HW and Lim JB collected and stored all the samples; Kong HY acquired the quantitative data of serum HB-EGF; Chung HW conducted statistical analysis and interpretation of all data; Chung HW and Lim JB drafted the manuscript and revised it critically for important intellectual content; all authors have given final approval of the version to be published; all authors agreed to be accountable for all aspects of the work.

Supported by Yonsei University College of Medicine for 2014, No. 3-2014-0115.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Jong-Baeck Lim, MD, PhD, Department of Laboratory Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, 211 Eonjuro, Gangnam-gu, Seoul 120-752, South Korea. jlim@yuhs.ac
Telephone: +82-2-20193533
Fax: +82-2-20578926

Received: June 2, 2014
Peer-review started: June 2, 2014
First decision: July 21, 2014
Revised: August 2, 2014
Accepted: September 18, 2014
Article in press: September 19, 2014
Published online: February 21, 2015

Abstract

AIM: To evaluate the clinical usefulness of soluble heparin-binding epidermal growth factor (sHB-EGF) as a serum biomarker for gastric cancer (GC).

METHODS: Serum sHB-EGF levels were measured by a commercially available human HB-EGF ELISA Kit and compared among 60 normal controls, 30 high-risk patients, 37 early gastric cancer (EGC), and 30 advanced gastric cancer (AGC) through ANOVA test. Correlations between serum sHB-EGF and clinicopathological features of GC were analyzed through Spearman's correlation. The diagnostic performance of serum sHB-EGF for GC was evaluated through receiver operating characteristic (ROC) curve and logistic regression analysis.

RESULTS: Serum sHB-EGF levels were significantly higher in AGC group (314.4 ± 127.5 pg/mL) than EGC (165.3 ± 123.2 pg/mL), high-risk (98.7 ± 67.3 pg/mL), and control (94.7 ± 83.6 pg/mL) groups (post-hoc Bonferroni, all $P < 0.001$). Serum sHB-EGF levels were also significantly higher in EGC group than high-risk ($P = 0.049$) and control ($P = 0.006$) groups. Clinically, serum sHB-EGF levels closely correlated with depth of invasion (T-stage, $\gamma_s = 0.669$, $P < 0.001$), lymph node metastasis (N-stage, $\gamma_s = 0.407$, $P = 0.001$), and distant metastasis (M-stage, $\gamma_s = 0.261$, $P = 0.030$). ROC curve and logistic regression analysis demonstrated a remarkable diagnostic potential of serum sHB-EGF.

CONCLUSION: Serum sHB-EGF is closely correlated with advanced stage GC and can be a promising serological biomarker for GC.

Key words: Biomarker; Diagnostic; Gastric cancer; Prognostic; Soluble heparin-binding EGF-like growth factor

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Early detection of gastric cancer (GC) is most important issue. Although endoscopic examination is an ideal, highly reliable technique for early detection of GC, it has limitation because of its high cost and invasiveness. Therefore, inexpensive, comfortable, reliable and less-invasive biomarkers need to be identified. Here, we reported that serum levels of soluble HB-EGF (sHB-EGF) closely correlated with advanced TNM stage and was higher in EGC than high-risk group. We also identified a remarkable diagnostic accuracy of serum sHB-EGF for GC. To our knowledge, this is the first study to validate sHB-EGF as a desirable serum biomarker for GC.


INTRODUCTION

Although the incidence of gastric cancer (GC) has decreased over the past few decades, it is still a serious health problem because it is the second most frequent cause of cancer-related deaths worldwide[1], which may be originated from that the prognosis of advanced gastric cancer (AGC) remains poor despite the recent advances in treatment strategies[2]. In contrast, the prognosis of early gastric cancer (EGC) is favorable[3]. These facts strongly support the clinical importance of early detection of GC. Endoscopic examination is an ideal, highly reliable technique for early detection of GC and its premalignant lesions[4]. However, its usefulness as a routine screening method is somewhat limited because of its high cost and the risk associated with this invasive procedure. Therefore, inexpensive, comfortable, reliable and less-invasive biomarkers such as accurate serological biomarker need to be identified.

Carcinoembryonic antigen (CEA), a well-known gastrointestinal tumor-related biomarker, was initially applied as a biomarker for GC. However, recent studies have found that CEA does not demonstrate the sensitivity or specificity needed to effectively screen for GC[5].

Activation of the epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) families is known to be associated with the progression of various tumor types[6]. Activation of EGF-EGFR axis is also associated with tumor growth, serosal invasion, and resultant poor prognosis of GC patients[7-9]. EGFR has seven ligands. Of these ligands, heparin-binding EGF-like growth factor (HB-EGF) is in particular thought to be associated with GC development and progression[10-13].

HB-EGF is a member of the EGF family[14]. It is initially synthesized as a membrane-anchored form (pro-HB-EGF), which is subsequently cleaved from the membrane by metalloproteinase to produce a mature soluble form of HB-EGF (sHB-EGF)[15]. Many in vitro studies demonstrated that sHB-EGF is a potent mitogen for several types of epithelial cells[16-19]. Several studies also demonstrated that HB-EGF is overexpressed in human GC cell lines and GC tissues[13,19,20]. Therefore, this growth factor has potentials as a biomarker for GC. Although tissue markers have high specificity, reproducibility, and reliability, serological biomarkers are preferable as a screening method for GC because tissue markers require invasive techniques such as endoscopy and biopsy. Because HB-EGF is released into circulation as a mature soluble form, this growth factor can be measured in serum, and serum levels of this soluble factor may reflect the disease progression in GC. However, there is little information about the serological levels of sHB-EGF according to gastric carcinogenic sequence.

In this study, we determined how serum levels of sHB-EGF related to the “gastritis-dysplasia-carcinoma” sequence of gastric carcinogenesis[21] and analyzed its correlations with clinicopathological features of GC. We also investigated the usefulness as a biomarker for GC compared with serum CEA.

MATERIALS AND METHODS

Subjects and clinical information
A total of 157 subjects from Yonsei University Health System were enrolled in this study. All subjects underwent upper gastrointestinal endoscopy (Types XQ-260, Olympus, Tokyo, Japan) with biopsy. The final diagnosis was made based on histological findings from biopsy or surgical specimens. All patients were diagnosed for the first time during the enrollment period, and blood samples were collected before they received any treatments. Blood samples were stored as serum fractions at -80 °C until analysis. The Institutional Review Board of Yonsei University Health System approved the current study, and written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Subjects who suffered from chronic diseases such as liver cirrhosis, chronic renal disease, and diabetes mellitus were excluded from this study. Subjects with other cancers and other gastrointestinal neoplasms such as gastrointestinal stromal tumors, mucosa-associated lymphoid tissue lymphomas, and neuroendocrine tumors were also excluded. Patients who previously received any treatment for GC or its premalignant lesions were also excluded.

Subjects were classified into the following four groups according to the “gastritis-dysplasia-carcinoma” sequence of gastric carcinogenesis[21]: control group,
which included normal mucosa or acute and chronic gastritis; high-risk group, which included intestinal metaplasia (IM) and dysplasia; EGC group; and AGC group. Both age and sex were matched in all groups. All patients in the cancer groups underwent imagining studies including chest X-ray, abdominal-pelvic helical computed tomography, and whole-body positron emission tomography to determine TNM stage. TNM stage for GC was evaluated according to the 7th International Union Against Cancer-TNM stage guidelines for GC[22] based on radiological studies or surgical findings. Helicobacter pylori (H. pylori) infection was determined by staining of gastric tissue with Giemsa solution (Sigma, MO, United States). Glandular atrophy and IM were diagnosed according to the updated Sydney classification[23], and pathological determination of differentiation status (well, moderate, poor, and signet-ring cell) was performed according to the Lauren classification.

**Measurement of serum CEA and HB-EGF levels**

Serum CEA levels were measured by the Beckman Access CEA assay (Beckman Coulter Inc., MN, United States). Serum sHB-EGF levels were measured by a commercially available human HB-EGF ELISA Kit (DY259, RD, MN, United States) according to the manufacturer’s instructions. Briefly, 96-well microplates were coated with capture antibody (80 μg/well, goat anti-human HB-EGF) at 4 °C for 16 h. After washing, the plates were blocked with Reagent Diluent (provided in kit) and then incubated for 1 h at room temperature (RT). After washing, 100 μL of diluted sample, standard, and control were added to each well. The microplates were then incubated for 2 h at RT. Subsequently, microplates were washed and then detection antibody was added (10 ng/well, biotinylated goat anti-human HB-EGF). The plates were then incubated for 2 h at RT. After washing, streptavidin-HRP was added and incubated for 20 min at RT in the dark place. Plates were then washed again, and 100 μL of chromogen (H₂O₂ and tetra-methylbenzidine) was added to each well. The enzyme reaction proceeded for 20 min at RT in the dark place. The chromogenic substrate reaction was stopped by the addition of stop solution (2 mol/L H₂SO₄) and the absorbance was read at 450/570 nm. The final values were calculated based on a calibration curve prepared from standards. The ELISA for sHB-EGF levels was tested in triplicate.

**Statistical analysis**

To calculate the appropriate sample size for each group, Russ Lenth’s interactive power/sample size online calculator was used. Under assuming that there were 4 comparison groups, the estimated standard deviation (SD) was 1, and the confidence level was 0.05, sample size of ≥ 30 in each group achieved a statistical power > 80% using one-way analysis of variance (ANOVA).

For statistical analysis for current data, SPSS version 20.0 (IBM Corp., NY, United States) was used. P values < 0.05 were considered statistically significant. Values (sHB-EGF, CEA) were expressed as the mean with the 25%-75% SD. Means of each group was compared by ANOVA test with multiple comparisons by using the post-hoc Bonferroni method. An independent sample t-test was used to compare the mean between the cancer groups vs non-cancer groups. Spearman’s correlation (coefficient, rₛ) was used to assess the relationship between continuous variables and non-continuous variables, and Pearson’s correlation (coefficient, r_p) was used to assess the relationship between continuous variables. Nominal data were compared by χ² test. The receiver operating characteristic (ROC) curves was conducted and area under the curve (AUC) was calculated to compare the diagnostic accuracy between serum sHB-EGF and serum CEA. Logistic regression analysis was performed to obtain the best sensitivity/specificity to predict the presence of GC as a single-marker or as a part of multiple-markers panel. Each marker was included as a linear term.

**RESULTS**

**Baseline characteristics of subjects and serum levels of sHB-EGF and CEA according to disease groups**

The 157 subjects are composed of 60 individuals/patients with normal mucosa or gastritis (control group), 30 patients with IM/dysplasia (high-risk group), 37 patients with EGC (EGC group), and 30 patients with AGC (AGC group). The control group was further subdivided into two subgroups; patients with normal mucosa/chronic superficial gastritis (CSG, n = 30) and patients with chronic atrophic gastritis (CAG, n = 30) because the risk of GC development was different between CSG and CAG. The normal mucosa/CSG group was also further subdivided into normal mucosa (n = 15) or CSG (n = 15) because gastric inflammation status may affect sHB-EGF levels comparing to normal mucosa. The clinical and histopathological features of subjects in each group are described in Table 1. There were no significant differences in distribution of age and sex, and the status of H. pylori infection among the disease groups (χ²; all P > 0.05). In the cancer groups, the location of primary tumor did not differ (P > 0.05), while histological differentiation, primary tumor size, and TNM stage were significantly different between the EGC and AGC groups (all P < 0.05).

Serum sHB-EGF levels increased along the GC carcinogenic sequence, and the differences among the groups were statistically significant (ANOVA, P < 0.001; Table 2). Serum sHB-EGF levels were significantly higher in the AGC group (314.4 ± 127.5 pg/mL) compared with those of EGC (165.3...
Table 1 Baseline characteristics of subjects in each group

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control(^{1}) (n = 60)</th>
<th>High-risk(^{1}) (n = 30)</th>
<th>EGC (n = 37)</th>
<th>AGC (n = 30)</th>
<th>P value(^{1})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical features</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (mean ± SD, yr)</td>
<td>56.5 ± 11.1</td>
<td>66.2 ± 7.6</td>
<td>58.3 ± 10.6</td>
<td>56.3 ± 10.3</td>
<td>0.856</td>
</tr>
<tr>
<td>Sex (male:female, n)</td>
<td>37:23</td>
<td>19:11</td>
<td>22:15</td>
<td>17:13</td>
<td>0.993</td>
</tr>
<tr>
<td>H. pylori infection (-/+, n)</td>
<td>35:25</td>
<td>17:13</td>
<td>22:15</td>
<td>20:10</td>
<td>0.887</td>
</tr>
<tr>
<td>Histopathological features</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histology (well/mod:poorly/signet)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Tumor location (lower:middle:upper)(^{2})</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Size of tumor (mean ± SD, cm)</td>
<td>39.9 ± 1.2</td>
<td>50.0 ± 1.3</td>
<td>5.0 ± 1.3</td>
<td>5.0 ± 1.3</td>
<td>0.010</td>
</tr>
<tr>
<td>T-stage (T1a:T1b:T2:T3:T4)</td>
<td>NS</td>
<td>NS</td>
<td>31:60:00:03</td>
<td>0:0:15:4:11</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>N-stage (N0:N1:N2:N3)</td>
<td>NS</td>
<td>NS</td>
<td>35:2:0:0</td>
<td>15:2:4:9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Distant metastasis (M0:M1)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>25:5</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Overall stage (I-II:III)</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

\(^{1}\)Tumor location is divided into three areas: lower third (antrum-angle), middle third (low body-middle body), and upper third (upper body-cardia). \(^{2}\)Control group includes individuals with normal mucosa or patients with simple chronic superficial gastritis and chronic atrophic gastritis. \(^{3}\)High-risk group included patients with intestinal metaplasia and dysplasia. \(^{4}\)Continuous data were compared by ANOVA test and nominal data by \(\chi^2\) test. \(P < 0.05\) (two-tailed) was considered statistically significant. AGC: Advanced gastric cancer; EGC: Early gastric cancer; H. pylori: Helicobacter pylori; Mod: Moderate-differentiated carcinoma; Poorly: Poorly-differentiated carcinoma; SD: Standard deviation; Signet: Signet ring cell carcinoma; Well: Well-differentiated carcinoma.

Table 2 Serum levels of soluble heparin-binding epidermal growth factor-like growth factor and carcinoembryonic antigen according to disease groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control(^{1}) (n = 60)</th>
<th>High-risk(^{1}) (n = 30)</th>
<th>EGC (n = 37)</th>
<th>AGC (n = 30)</th>
<th>P value(^{1})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum sHB-EGF(^{2}) (pg/mL)</td>
<td>94.7 ± 83.6</td>
<td>96.7 ± 86.3</td>
<td>165.3 ± 123.2</td>
<td>314.4 ± 127.5</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Serum CEA(^{2}) (ng/mL)</td>
<td>1.8 ± 1.5</td>
<td>2.2 ± 1.1</td>
<td>2.4 ± 1.4</td>
<td>4.5 ± 5.1</td>
<td>0.001</td>
</tr>
</tbody>
</table>

\(^{1}\)All tested values are expressed as the mean ± standard deviation. \(^{2}\)Control group includes individuals with normal mucosa or patients with simple chronic superficial gastritis and chronic atrophic gastritis. \(^{3}\)High-risk group included patients with intestinal metaplasia and dysplasia. \(^{4}\)One-way analysis of variance (ANOVA) test with the multiple comparisons by the post-hoc Bonferroni method is applied to compare the differences in means among disease groups. \(P < 0.05\) (two-tailed) was considered statistically significant. AGC: Advanced gastric cancer; EGC: Early gastric cancer; CEA: Carcinoembryonic antigen; sHB-EGF: Soluble heparin-binding EGF-like growth factor.

Table 5 shows that serum sHB-EGF levels were not affected by sex (\(\gamma_p = 0.138, P = 0.076\)) or the status of H. pylori infection (\(\gamma_p = -0.54, P = 0.486\)), whereas these levels were negatively correlated with age (\(\gamma_p = -0.265, P = 0.001\)). However, serum sHB-EGF levels were not closely correlated with age when analysis was performed in just non-cancer groups (\(\gamma_p = 0.108, P = 0.313\)). In contrast, when analysis was performed within the cancer groups, the serum sHB-EGF levels were negatively correlated with age (\(\gamma_p = -0.314, P = 0.010\)). This result implies that serum sHB-EGF levels are affected by the age of patients with GC; relatively younger patients with GC had more highly elevated sHB-EGF levels compared with relatively older patients with GC. On the other hand, serum CEA levels were not affected by sex, age and the status of H. pylori infection (all \(P > 0.05\); Table 5).

Histopathologically, there were no significant relationships between serum sHB-EGF levels and the histological differentiation of GC (Lauren classification system), although sHB-EGF levels tend to be higher in diffuse-type than in intestinal-type (\(\gamma_p = 0.214, P = 0.078\); Table 5). Serum sHB-EGF levels were not also affected by primary tumor location (\(\gamma_p = -0.054, P = 0.652\); Table 5).

On the other hand, serum sHB-EGF levels were...
closely correlated with depth of invasion (T-stage, \( P = 0.669, P < 0.001 \)), lymph node metastasis (N-stage, \( P = 0.407, P = 0.001 \)), distant metastasis (M-stage, \( P = 0.261, P = 0.030 \)), and overall stage (\( P = 0.570, P < 0.001 \)) respectively (Table 5). To analyze the relationship between serum sHB-EGF levels and primary GC size, patients were divided into 3 groups based on the tumor size: < 3 cm, 3-5 cm, and > 5 cm. Table 5 shows that primary GC size was positively correlated with serum sHB-EGF levels (\( P = 0.237, P = 0.048 \)). On the other hand, serum CEA levels were only correlated with tumor size (\( P = 0.382, P = 0.006 \)) and distant metastasis (\( P = 0.362, P = 0.002 \)). Collectively, histopathological results suggest that serum sHB-EGF levels were closely correlated with advanced stage and poor prognosis of GC.

**Diagnostic accuracy of serum sHB-EGF levels for prediction of GC**

ROC curve was generated and AUCs were calculated to compare the diagnostic accuracy of serum sHB-EGF with serum CEA for prediction of GC (Figure 1). The AUC of serum sHB-EGF was 0.85 (95%CI: 0.79-0.91), and those of serum CEA was 0.64 (95%CI: 0.55-0.73). This analysis indicates that serum sHB-EGF has a higher diagnostic accuracy to predict the presence of GC compared with CEA.

Logistic regression analysis further confirmed the remarkable diagnostic accuracy of serum sHB-EGF for GC; the sensitivity and specificity of serum sHB-EGF levels for diagnosis of GC were 76.1% and 76.5% (cut-off point, 0.38; Table 7). These values are superior to those of serum CEA (sensitivity, 62.1%; specificity, 51.8%; cut-off point, 0.38). When serum sHB-EGF was combined with serum CEA, the sensitivity was slightly increased; the sensitivity was 77.3% and specificity was 76.5% (cut-off point, 0.38), respectively. When serum sHB-EGF was combined with serum CEA, the sensitivity was slightly increased; the sensitivity and specificity were 77.3% and 76.5% (cut-off point, 0.38).

Collectively, serum sHB-EGF exhibited a remarkable

---

**Table 3** Serum levels of soluble heparin-binding epidermal growth factor-like growth factor between normal mucosa/chronic superficial gastritis and chronic atrophic gastritis or between normal mucosa and chronic superficial gastritis

<table>
<thead>
<tr>
<th>Groups</th>
<th>Serum sHB-EGF (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal mucosa/CSG (n = 30)</td>
<td>86.4 ± 73.5</td>
</tr>
<tr>
<td>CAG (n = 30)</td>
<td>102.9 ± 93.1</td>
</tr>
<tr>
<td>( P ) value(^2)</td>
<td>0.449</td>
</tr>
<tr>
<td>Normal mucosa (n = 15)</td>
<td>83.1 ± 59.0</td>
</tr>
<tr>
<td>CSG (n = 15)</td>
<td>89.7 ± 87.6</td>
</tr>
<tr>
<td>( P ) value(^2)</td>
<td>0.811</td>
</tr>
</tbody>
</table>

\(^1\) Tested value is expressed as the mean ± SD. \(^2\) An independent sample t-test is applied to compare the differences of means between two groups. \( P < 0.05 \) (two-tailed) was considered statistically significant. sHB-EGF: Soluble heparin-binding EGF-like growth factor.

---

**Table 4** Serum levels of soluble heparin-binding epidermal growth factor-like growth factor and carcinoembryonic antigen between non-cancer and cancer groups

<table>
<thead>
<tr>
<th>Groups</th>
<th>Non-cancer (^2) (n = 90)</th>
<th>Cancer (^2) (n = 67)</th>
<th>( P ) value(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum sHB-EGF(^3) (pg/mL)</td>
<td>96.0 ± 78.2</td>
<td>232.1 ± 144.9</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Serum CEA(^3) (ng/mL)</td>
<td>1.9 ± 1.4</td>
<td>3.3 ± 3.7</td>
<td>0.004</td>
</tr>
</tbody>
</table>

\(^1\) All tested values are expressed as the mean ± SD. \(^2\) Non-cancer groups include normal/gastritis group and IM/dysplasia group. \(^3\) Cancer groups include early gastric cancer (EGC) and advanced gastric cancer (AGC) groups. \(^4\) An independent sample t-test is applied to compare the differences of means between non-cancer and cancer groups. \( P < 0.05 \) (two-tailed) was considered statistically significant. CEA: Carcinoembryonic antigen; sHB-EGF: Soluble heparin-binding EGF-like growth factor.
diagnostic accuracy to predict GC both as a single biomarker and as a part of multiple-markers panel in GC (Table 7).

**DISCUSSION**

Increased EGFR levels are associated with poor prognosis in patients with GC,[10,24]. HB-EGF, a ligand of the EGFR family, is initially synthesized as a pro-HB-EGF, a membrane-bound precursor form. It is later released into circulation as a soluble, mature form[15]. This shB-EGF activates EGFR and acts as a potent growth factor[16-19]. HB-EGF is a critical molecular component of many normal physiological processes[14]. However, uncontrolled HB-EGF expression is linked to tumor formation. Thus, HB-EGF may become a promising biomarker or treatment target for cancer. Several studies have shown that HB-EGF is overexpressed in GC tissues and GC cell lines[20], and overexpressed HB-EGF is correlated with far-advanced stage of GC[10]. However, there is little quantitative data demonstrating the clinical significance of serum shB-EGF in relation to GC tumorigenesis and progression such as TNM stage. There is also little known about the usefulness of this soluble factor as a biomarker for GC. In this study, we gathered quantitative information about the clinical significance of serum shB-EGF levels in GC and validated serum shB-EGF as a useful and reliable serological biomarker for GC.

We divided the subjects into 4 disease groups based on the theory of gastric carcinogenesis (gastritis-dysplasia-carcinoma)[21]: normal mucosa/gastritis (control), IM/dysplasia (high-risk), EGC, and AGC. Control group included subjects with normal gastric mucosa, simple CSG, and CAG because these patients have a relatively lower risk of GC development compared with IM/dysplasia. We did not subdivide patients into IM and dysplasia (adenoma) in the high-risk group because the number of subjects in each group was too small to be determined statistically significant. We divided the cancer patients into EGC and AGC groups because the prognosis is definitively different between EGC and AGC[1,3]. Interestingly, we observed that serum shB-EGF levels increased along the carcinogenic sequence, although there was no statistically significant difference between the high-risk and control groups (Table 2).

Table 7  Logistic regression determination of the diagnostic accuracy of serum soluble heparin-binding epidermal growth factor-like growth factor compared with those of serum carcinoembryonic antigen for prediction of gastric cancer

<table>
<thead>
<tr>
<th>Markers</th>
<th>Cut-off point</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum shB-EGF</td>
<td>0.38</td>
<td>76.1%</td>
<td>76.5%</td>
</tr>
<tr>
<td>Serum CEA</td>
<td>0.38</td>
<td>62.1%</td>
<td>51.8%</td>
</tr>
<tr>
<td>Serum shB-EGF + CEA</td>
<td>0.38</td>
<td>77.3%</td>
<td>76.5%</td>
</tr>
</tbody>
</table>

Each marker is included as a linear term and evaluated as a panel from one to two markers combination. Cut-off point means the probability cut-off point to classify subjects as having gastric cancer (GC) or not in binary logistic regression. CEA: Carcinoembryonic antigen; shB-EGF: Soluble heparin-binding epidermal growth factor-like growth factor.

To validate serum shB-EGF as a desirable serum biomarker to predict the presence of GC, we generated ROC curves and calculated AUC values. We also performed logistic regression analysis to determine the best sensitivity and specificity for prediction of GC (Figure 1 and Table 7). We compared the results from shB-EGF with the results from CEA, a well-known gastrointestinal tumor biomarker. Sensitivity/specificity of serum CEA for detection of GC were only around 50%-60% (Table 7), consistent with other previous studies[5,25]. However, the sensitivity and specificity of serum shB-EGF were both greater than 75% (Table 7). When serum shB-EGF was combined with serum CEA, the sensitivity was slightly elevated (76.1%–77.3%, Table 6). These are notable results compared with previous GC biomarker studies[5,25-27].

Clinicopathologically, serum shB-EGF levels were closely correlated with depth of invasion, lymph
node metastasis, distant metastasis, and primary tumor size (Table 5). This implies that sHB-EGF is involved not only in GC tumorigenesis, but also in GC expansion, invasion, and metastasis. This result is consistent with previous studies. To our knowledge, this is the first study to evaluate serum sHB-EGF levels quantitatively according to the gastric carcinogenic sequence, to analyze the correlations between serum sHB-EGF and clinicopathological features of GC, such as TNM stage, and to validate serum sHB-EGF as a desirable serological biomarker for GC.

Previous studies reported that sHB-EGF levels were influenced by H. pylori infection. However, in our study, serum sHB-EGF levels were not correlated with the status of H. pylori infection (Table 5). This discrepancy may be originated from the differences in the genetic background of enrolled subjects or different strains of H. pylori between the two studies because variation in the clinical presentation of H. pylori infection is attributable to strain diversity and host susceptibility. However, we did not study about this in the current study.

A previous study showed that the activity of pro-HB-EGF was higher in intestinal type of GC compared with diffuse type of GC. However, the relationship between the activity of sHB-EGF levels and histological differentiation has not been yet evaluated in previous studies. In this study, we observed that serum sHB-EGF levels tend to be higher in diffuse type than intestinal type of GC although it was not statistically significant (P = 0.078, Table 5). A study group reported that sHB-EGF promotes peritoneal carcinoatasis in patients with GC. Peritoneal carcinoatasis occurs frequently in patients with diffuse scirrhous type of GC. These past reports support our current results. However, to confirm this, a further study may be necessary in the future.

We also observed that serum sHB-EGF levels were inversely correlated with age in GC patients (Table 5), whereas this value was not affected by age in non-cancer groups (Table 6), which implies that age itself may not affect the serum levels of sHB-EGF. Rather, higher levels of serum sHB-EGF in relatively younger GC patients than older patients may suggest that serum sHB-EGF may contribute to GC carcinogenesis especially in young age. However, we cannot currently explain the underlying mechanism of this phenomenon.

One of limitations of this study is the relatively small sample sizes, although statistical power of the current sample size of each group was > 80%. Additionally, we did not evaluate the relationship between serum sHB-EGF levels and prognosis of GC patients by directly comparing overall survival because the observation period was too short to evaluate the survival of the patients with GC. However, Table 5 showing the close correlations between high-levels of serum sHB-EGF and the presence lymph node and distant metastasis may support the correlation between high-levels of serum sHB-EGF and poor prognosis of GC indirectly because these two factors are the most important prognostic indicators for GC patients.

In conclusion, in this study, we evaluated the clinical significance of serum sHB-EGF levels in GC and validated serum sHB-EGF as a promising diagnostic and prognostic biomarker for GC. Our results also provide a rationale for blockade of sHB-EGF as a promising effective treatment target for GC, especially for advanced GC. Actually, several past studies have shown a remarkable antitumor effect of an HB-EGF inhibitor alone or in combination with various anticancer agents in cancer including GC. To confirm this, we will conduct a large-scaled study in the future.

**COMMENTS**

**Background**

Early detection of gastric cancer (GC) is the most important clinical issue. Although endoscopic examination is an ideal, highly reliable technique for early detection of GC, it has some limitations as a routine screening method because of the risk associated with invasive procedure. Therefore, identification of inexpensive, reliable and less-invasive serum biomarkers is a great clinical challenge. However, research is still underway to identify effective serum biomarkers for GC.

**Research frontiers**

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) has been thought to be associated with GC development and progression, and demonstrated to be overexpressed in human GC tissues. Because HB-EGF can be released into circulation as a mature soluble form of HB-EGF (sHB-EGF), it can be measured in serum and can be used as a serum biomarker for GC. The authors determined how serum levels of sHB-EGF related to the ‘gastritis-dysplasia-carcinoma’ sequence of gastric carcinogenesis and validated its usefulness as a biomarker for GC compared with serum CEA, a classic biomarker for gastrointestinal tumors.

**Innovations and breakthroughs**

Recent reports showed that increased epidermal growth factor receptor levels are associated with poor prognosis in patients with GC and HB-EGF expression is linked to tumor formation although HB-EGF is a critical molecular component of many normal physiological processes. Thus, HB-EGF may become a promising biomarker or treatment target for GC. Several studies have shown that HB-EGF is overexpressed in GC tissues, and overexpressed HB-EGF is correlated with far-advanced stage of GC. However, there is little quantitative data demonstrating the clinical significance of serum sHB-EGF in relation to GC tumorigenesis and progression such as TNM stage. This is the first study to evaluate serum sHB-EGF levels quantitatively according to the gastric carcinogenic sequence, to analyze the correlations between serum sHB-EGF and clinicopathological features of GC, such as TNM stage, and to validate serum sHB-EGF as a desirable serological biomarker for GC.

**Applications**

The study results suggest that sHB-EGF are closely correlated with advanced TNM stage and higher in early gastric cancer (EGC) group than high-risk group, and higher in advanced gastric cancer group than EGC group. Additionally, this study demonstrated a remarkable diagnostic accuracy of serum sHB-EGF for GC.

**Peer-review**

This is an interesting manuscript with innovative endpoint and potential clinical impact. In this manuscript, authors studied the clinical usefulness of soluble heparin-binding EGF-like growth factor as a biomarker for GC. HB-EGF is overexpressed in several cancer cell lines and cancer tissues including human GC tissues. HB-EGF is also reported to be involved in malignant phenotype.
and chemo-resistance of cancer cells. Therefore this study would be useful to develop a useful biomarker for GC diagnosis.

REFERENCES


**P- Reviewer:** Antonakopoulos N, Mekada E  **S- Editor:** Qi Y  **L- Editor:** A  **E- Editor:** Zhang DN